More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Open Access
- 5 January 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 92 (1) , 76
- https://doi.org/10.1093/jnci/92.1.76
Abstract
CYP3A4 is a member of the cytochrome P450 supergene family that mediates the metabolism of numerous compounds involved in human carcinogenesis, including steroid hormones such as testosterone. Recently, a variant in the 5′ regulatory region of CYP3A4 (CYP3A4-V) was reported to confer higher stage prostate tumors compared with homozygous wild-type CYP3A4 (CYP3A4-W) in both Caucasians and African-Americans (1,2). To date, these associations have not been supported by data that address the functional significance of this polymorphism.Keywords
This publication has 5 references indexed in Scilit:
- Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4Clinical Pharmacology & Therapeutics, 1999
- RESPONSE: Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4JNCI Journal of the National Cancer Institute, 1999
- Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4JNCI Journal of the National Cancer Institute, 1999
- Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory RegionBiochemical and Biophysical Research Communications, 1999
- Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4JNCI Journal of the National Cancer Institute, 1998